转运蛋白18kDa配体依替福辛治疗抑郁障碍:双盲、随机、安慰剂对照的概念验证研究
本研究是一项随机、安慰剂对照、双盲、单中心试验,旨在首次验证转运蛋白18kDa(TSPO)配体依替福辛能否快速抗抑郁,并探索神经甾体生成、神经网络调节等机制。主要终点为汉密尔顿抑郁量表(HAMD-21)评分达到最大效应50%的时间点(ET50)。每组需20例,假设脱落率10-20%,共随机50例。
要点
- 随机、双盲、安慰剂对照、单中心试验,评估依替福辛2周治疗抑郁障碍。
- 主要终点为HAMD-21评分达到最大效应50%的时间点(ET50)。
- 每组需20例以检测疗效变化约5%和ET50变化约10%,把握度70%。
核心结论
- 本研究将为TSPO配体依替福辛治疗抑郁障碍的潜力提供首个概念验证证据。
研究设计与样本
- 随机、安慰剂对照、双盲、单中心试验,依替福辛2周治疗抑郁患者。
- 入组标准为18至65岁、单相或双相抑郁障碍、无其他主要精神科诊断、无急性神经/躯体疾病或终生药物/酒精依赖的男性或女性。
- 每组需20例以检测疗效变化约5%和ET50变化约10%,把握度70%。
- 假设脱落率10-20%,共随机50例。
- 研究在雷根斯堡大学精神病学与心理治疗系开展。
关键数值与推荐
- 主要终点为HAMD-21评分达到最大效应50%的时间点(ET50)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent developments suggest that neurosteroids may achieve rapid antidepressant effects. As such, neurosteroidogenesis mediated by the translocator protein 18 kDa (TSPO) might constitute a promising option for the treatment of depression. Therefore, the current clinical trial aims to get the first evidence of whether TPSO ligands promote rapid antidepressant effects. Furthermore, we study which mechanisms of action, e.g., modulation of distinct neuronal networks, neurosteroidogenesis, endocrinological mechanisms, TSPO expression or microbiome composition, contribute to their putative antidepressant effects. METHODS: This is a randomized, placebo-controlled, double-blind single-center trial of 2-week treatment with the TSPO ligand etifoxine versus placebo in depressive patients. Main eligibility criteria: male or female individuals aged 18 to 65 years with unipolar/bipolar depressive disorder with no other psychiatric main diagnosis or acute neurological/somatic disorder or drug/alcohol dependence during their lifetime. The primary endpoint is the time point at which 50% of the maximal effect has occurred (ET50) estimated by the scores of the Hamilton Depression Scale (HAMD-21). A total of 20 patients per group are needed to detect changes of therapeutic efficacy about 5% and changes of ET50 about 10% with a power of 70%. Assuming a drop-out rate of 10-20%, 50 patients will be randomized in total. The study will be conducted at the Department of Psychiatry and Psychotherapy of the University of Regensburg. DISCUSSION: This study will provide a first proof-of-concept on the potential of the TSPO ligand etifoxine in the treatment of depressive disorders. TRIAL REGISTRATION: Clinical Trials Register (EudraCT number: 2021-006773-38 , registration date: 14 September 2022) and German Register of Clinical Studies (DRKS number: DRKS00031099 , registration date: 23 January 2023).
引用
- Brunner LM, Riebel M, Wein S, et al. The translocator protein 18kDa ligand etifoxine in the treatment of depressive disorders-a double-blind, randomized, placebo-controlled proof-of-concept study. Trials. 2024. PMID: 38650030. doi:10.1186/s13063-024-08120-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。